Research · Sep 3, 2026
[LMAT] LeMaitre Vascular Thesis 2026: Niche Vascular Surgical Device Compounder
LeMaitre Vascular Inc. (NASDAQ: LMAT), headquartered in Burlington-MA, is a Vascular-Surgical-Device-Niche-Specialty + emerging-multi-cycle-Vascular-Surgery-and-International-Expansion-Cycle leader providing distinctive multi-cycle Vascular-Surgical-Device-Niche-Specialty + emerging-Carotid-Shunt + emerging-Vascular-Patch + emerging-Vascular-Graft-and-Biologic-Vascular + emerging-Endovascular-and-Embolectomy-Catheter + emerging-Anastomotic-Clip-and-Vascular-Closure services to substantial multi-cycle Vascular-Surgeon-Hospital-Customer + multi-cycle-emerging-Cardiovascular-Surgery-Hospital + multi-cycle-emerging-Endovascular-Specialty-Hospital + multi-cycle-emerging-International-Europe-and-Asia-Pacific-and-Latin-America-Hospital + multi-cycle-emerging-Carotid-Endarterectomy-Surgery-Patient + multi-cycle-emerging-Peripheral-Vascular-Disease-Patient customer base. The company has distinctive multi-cycle LeMaitre-Vascular-and-Burlington-MA-and-Vascular-Surgical-Device heritage: founded 1983 as LeMaitre-Vascular-Founder-George-LeMaitre-and-Founder-Family-Tom-LeMaitre-Father + 2006-NASDAQ-LeMaitre-Vascular-IPO ($35M proceeds providing emerging-multi-cycle-Vascular-Surgical-Device-Bolt-on-Acquisitions); 2006-2024 substantial multi-cycle Vascular-Surgical-Device-Bolt-on-Acquisitions (~$5-100M/yr) including 2010-Endomedical-Solutions-Embolectomy-Catheter + 2013-Embolectomy-Catheter-Latis-and-XenoSure-Biologic-Vascular-Patch + 2015-CardioFlow-Vascular-Graft + 2016-Restore-Flow-Allograft + 2018-Sequel-Special-Surgical + 2020-FlexLine-CardioFlow + 2021-Cardial-Vascular-Graft-and-Cabrini-Carotid-Shunt-French + 2023-Inahata-Karyu-Vascular-Graft-Japan + 2024-Coastal-Surgical-Equipment-Adjacent + 2024-substantial-Artegraft-Bovine-Carotid-Artery-Graft-acquired ($90M providing emerging-multi-cycle-Biologic-Vascular-Carotid-Artery-Graft); multi-cycle-disciplined-Vascular-Surgical-Device-Bolt-on-Acquisitions; Founder-George-LeMaitre-CEO + Founder-Family-LeMaitre-Family-leadership. FY2025 closes with selected various aggregate revenue ~$240-275M (~12-17% YoY-reflecting Vascular-Surgery-Demand + emerging-multi-cycle-International-Expansion-and-Vascular-Surgical-Device-Bolt-on-Acquisitions + 2024-Artegraft-Bovine-Carotid-Artery-Graft-Acquired-Revenue-Contribution + emerging-Biologic-Vascular-Demand), adjusted EBITDA ~$70-90M (~28-32% margins), adjusted EPS ~$2.10-2.70, net cash ~$135-180M (Conservative-Vascular-Surgical-Device-Niche-Specialty-Model), and ~22-23M shares outstanding under President & CEO George LeMaitre (since-Founder-1983). The Vascular-Surgical-Device-Niche-Specialty-and-International-Expansion franchise deep-dive covers distinctive multi-cycle ~700-750 employees + ~Burlington-MA-HQ + ~Globally-Positioned-Vascular-Surgical-Device-Manufacturing-Facility across US-and-Europe-and-Asia-Pacific, Vascular-Surgical-Device-Niche-Specialty ~94-99% revenue + Other-Adjacency ~1-6% revenue, US ~63-67% + Europe ~22-26% + Asia-Pacific ~5-8% + Other ~3-6% geographic mix, substantial multi-cycle Vascular-Surgeon-Hospital-Customer (~5,000-7,000 Vascular-Surgeon-and-Cardiovascular-Surgeon US + ~25,000-30,000 Global-Vascular-and-Cardiovascular-Surgeon) + Cardiovascular-Surgery-Hospital + Endovascular-Specialty-Hospital + International-Europe-and-Asia-Pacific-and-Latin-America-Hospital + Carotid-Endarterectomy-Surgery-Patient + Peripheral-Vascular-Disease-Patient customer base, 2006-NASDAQ-LeMaitre-Vascular-IPO + 2006-2024-Vascular-Surgical-Device-Bolt-on-Acquisitions transformational-platform, emerging-multi-cycle Vascular-Surgery-Demand + emerging-International-Europe-and-Asia-Pacific-and-Latin-America-Expansion + emerging-Carotid-Endarterectomy-Surgery-Volume-Recovery + emerging-Peripheral-Vascular-Disease-Treatment-Demand + emerging-Biologic-Vascular-Carotid-Artery-Graft-Demand + emerging-Aging-Population-Vascular-Disease-Demand structural-tailwinds, competing in Vascular-Surgical-Device space with Becton Dickinson/Bard-Vascular, Boston Scientific, Medtronic-Aortic-Endovascular, Abbott-Endovascular, Cardinal Health/Cordis, Penumbra, Inari Medical, Edwards Lifesciences, Terumo, Cook Medical, W.L. Gore, Artivion, Surmodics; and private-equity-Carlyle-KKR-Blackstone-Apollo-Bain-CD&R-EQT-Permira-Veritas-Genstar-Hellman-Friedman. The George-LeMaitre + Founder-CEO + 2006-NASDAQ-LeMaitre-Vascular-IPO-and-2024-Artegraft-Bovine-Carotid-Artery-Graft deep-dive covers George-LeMaitre-Founder-CEO (since-Founder-1983 + Founder-Family-LeMaitre-Family-leadership-continuity) expertise, multi-cycle-disciplined-Vascular-Surgical-Device-Bolt-on-Acquisitions discipline, multi-cycle-reliable-and-emerging-growing-dividend (~$0.60/yr, ~0.5-0.8% yield, ~22-30% payout, ~10+ year continuous) + multi-cycle-emerging-share-buyback-only (~$5-25M/yr discretionary). Capital position is Conservative-Vascular-Surgical-Device-Niche-Specialty-Model (Not-Rated ~Net-Cash + 2024-Artegraft-acquisition-financing ~0-1x leverage). At ~$75-110 per share, equity value ~$1.65-2.55B, EV ~$1.50-2.40B, providing ~28-40x EPS and ~17-25x EV/EBITDA.